Inscrivez-vous 01 49 36 46 20
appel-offre
appel-offre
 
            
Date de publication : 20/11/2020
Date de péremption :
Type de procédure : Attribution d’un marché sans publication préalable d’un avis de marché
Type de document : Avis en cas de transparence ex ante volontaire
NORVÈGE
appel-offre

Norvège-Vadsø: Produits pharmaceutiques

2020/S 227-560372  (Source TED)
 
 
V  E  R  S  I  O  N      F  R  A  N  C  A  I  S  E
TX: 20/11/2020 S227 Norvège-Vadsø: Produits pharmaceutiques 2020/S 227-560372 Avis en cas de transparence ex ante volontaire Fournitures
 
 
Section I: Pouvoir adjudicateur/entité adjudicatrice
I.1) Nom et adresses Nom officiel: Sykehusinnkjøp HF Numéro national d'identification: 916879067 Adresse postale: Postboks 40 Ville: Vadsø Code NUTS: NO NORGE Code postal: 9811 Pays: Norvège Point(s) de contact: Ninja Elise Seippel Courriel: ninja.elise.seippel@sykehusinnkjop.no Téléphone: +47 78950700 Adresse(s) internet:
Adresse principale: https://permalink.mercell.com/143167039.aspx Adresse du profil d'acheteur: http://www.sykehusinnkjop.no/
I.4) Type de pouvoir adjudicateur Organisme de droit public
I.5) Activité principale Santé
 
 
Section II: Objet
II.1) Étendue du marché
II.1.1) Intitulé:
Calcium Folinate for National Stand-by Stores Numéro de référence: 2020/1784
II.1.2) Code CPV principal 33600000 Produits pharmaceutiques
II.1.3) Type de marché Fournitures
II.1.4) Description succincte:
The government has decided that establish two levels of medicine stand-by in Norway. A decision has been made in project B180 (National Stand-by Stores of Medicines), which is owned by Helse Vest RHF and managed by Sjukehusapoteka Vest HF, that a national stand-by must be established for several selected medicines. This means that stand-by stores must be developed as soon as possible. The time aspect is central to stand-by considerations and in light of the ongoing SARA-CoV-2 pandemic. This voluntary ex-ante transparency notice is for calcium folinate (ATC V03AF03).
II.1.6) Information sur les lots Ce marché est divisé en lots: non
II.1.7) Valeur totale du marché (hors TVA) Valeur hors TVA: 70 000.00 NOK
II.2) Description
II.2.3) Lieu d'exécution Code NUTS: NO01 Oslo og Akershus
II.2.4) Description des prestations:
Sykehusinnkjøp HF, medicines division (Sykehusinnkjøp), is procuring and obtaining tenders for health company financed medicines. Sykehusinnkjøp has been given a mandate to procure the medicine. Sykehusinnkjøp has previously announced and held an open tender contest for special pharmaceutical preparations ('LIS 2001b non-parenteral special pharmaceutical preparations') - (the contest). The contest included the mentioned medicine, as the tender documentation annex 3 - 'Active Ingredients List' requested tenders for the active ingredient (the medicine or reasonable alternatives). Sykehusinnkjøp therefore believes that there are grounds to make the procurement without a contest. The basis for the grounds are in accordance with the public procurement regulations, Section 13-4 a), c.f., Section 13-3. Tenders were not received in the above-mentioned contest for the active ingredient in question (medicine or reasonable alternatives), and this part of the contest must therefore be marked as unsuccessful. Sykehusinnkjøp has now examined which relevant medicines fulfil the regulatory requirements in Norway. If a medicine has a marketing licence in Norway, you cannot just procure an alternative medicine with a marketing licence in another country in the EU/EEA area. This is in the law on medicines, etc., Sections 8 and 10, sml. regulations on medicines chapter
   2.  This is further connected to Sykehusinnkjøp as a medicine intermediary having a right to its operations, c.f., the regulations on wholesaler operations with medicines, Section 33. According to www.legemiddelsok.no there are no other companies that the Supplier that have a marketing licence for the medicine in Norway. Sykehusinnkjøp has assessed that no other possible tenderers of the medicine will be able to fulfil the regulatory requirements in Norway (marketing licence in Norway), and be able to deliver so that the contract is fulfilled by the contracting authority's required date, and that there are no reasonable alternatives to the medicine. It is, therefore, objectively impossible to hold an ordinary contest or a contest in accordance with the public procurement regulations, Section 13-3. The scope of the contract is not larger than necessary. Based on this, Sykehusinnkjøp intends to enter into a contract between Helse Vest RHF and the Supplier for the procurement of the medicine. Sykehusinnkjøp requests that those who have objections to this voluntary ex-ante transparency notice submit feedback before the waiting period, which is set to 10 days calculated from the day after the publication of the voluntary ex-ante transparency notice. If no objections are received, a contract will be signed after the waiting period has expired. www.legemiddelsok.no
II.2.5) Critères d'attribution Prix
II.2.11) Information sur les options Options: non
II.2.13) Information sur les fonds de l'Union européenne
Le contrat s'inscrit dans un projet/programme financé par des fonds de l'Union européenne: non
II.2.14) Informations complémentaires
 
 
Section IV: Procédure
IV.1) Description
IV.1.1) Type de procédure Attribution d'un marché sans publication préalable d'un avis d'appel à la concurrence au Journal officiel de l'Union européenne (dans les cas énumérés ci-dessous) Explication:
Sykehusinnkjøp HF, medicines division (Sykehusinnkjøp), is procuring and obtaining tenders for health company financed medicines. Sykehusinnkjøp has been given a mandate to procure the medicine. Sykehusinnkjøp has previously announced and held an open tender contest for special pharmaceutical preparations ('LIS 2001 Special Pharmaceutical Preparations'), (the contest). The contest included the mentioned medicine, as the tender documentation annex 3 - 'Active Ingredients List' requested tenders for the active ingredient (the medicine or reasonable alternatives). Sykehusinnkjøp therefore believes that there are grounds to make the procurement without a contest. The basis for the grounds are in accordance with the public procurement regulations, Section 13-4 a), c.f., Section 13-3. Tenders were not received in the above-mentioned contest for the active ingredient in question (medicine or reasonable alternatives), and this part of the contest must therefore be marked as unsuccessful. Sykehusinnkjøp has now examined which relevant medicines fulfil the regulatory requirements in Norway. If a medicine has a marketing licence in Norway, you cannot just procure an alternative medicine with a marketing licence in another country in the EU/EEA area. This is in the law on medicines, etc., Sections 8 and 10, sml. regulations on medicines chapter
   2.  This is further connected to Sykehusinnkjøp as a medicine intermediary having a right to its operations, c.f., the regulations on wholesaler operations with medicines, Section 33. According to www.legemiddelsok.no there are no other companies that the supplier that have a marketing licence for the medicine in Norway. Sykehusinnkjøp has assessed that no other possible tenderers of the medicine will be able to fulfil the regulatory requirements in Norway (marketing licence in Norway), and be able to deliver so that the contract is fulfilled by the contracting authority's required date, and that there are no reasonable alternatives to the medicine. It is, therefore, objectively impossible to hold an ordinary contest or a contest in accordance with the public procurement regulations, Section 13-3. The scope of the contract is not larger than necessary. Based on this, Sykehusinnkjøp intends to enter into a contract between Helse Vest RHF and the Supplier for the procurement of the medicine. Sykehusinnkjøp requests that those who have objections to this voluntary ex-ante transparency notice submit feedback before the waiting period, which is set to 10 days calculated from the day after the publication of the voluntary ex-ante transparency notice. If no objections are received, a contract will be signed after the waiting period has expired. www.legemiddelsok.no
IV.1.3) Information sur l'accord-cadre
Le marché implique la mise en place d'un accord-cadre
IV.1.8) Information concernant l'accord sur les marchés publics (AMP)
Le marché est couvert par l'accord sur les marchés publics: oui
IV.2) Renseignements d'ordre administratif
 
 
Section V: Attribution du marché/de la concession
Marché nº: 1
V.2) Attribution du marché/de la concession
V.2.1) Date d'attribution du marché:
15/11/2020
V.2.2) Informations sur les offres
Le marché a été attribué à un groupement d'opérateurs économiques: non
V.2.3) Nom et adresse du titulaire/concessionnaire Nom officiel: Teva Norway AS Numéro national d'identification: 982222311 Ville: Sandvika Code NUTS: NO01 Oslo og Akershus Code postal: 1337 Pays: Norvège
Le titulaire/concessionnaire sera une PME: non
V.2.4) Informations sur le montant du marché/du lot/de la concession (hors TVA) Valeur initiale totale estimée du marché/du lot/de la concession: 70 000.00 NOK Valeur totale du marché/du lot/de la concession: 70 000.00 NOK
V.2.5) Information sur la sous-traitance
 
 
Section VI: Renseignements complémentaires
VI.3) Informations complémentaires:
VI.4) Procédures de recours
VI.4.1) Instance chargée des procédures de recours Nom officiel: Øst-Finnmark tingrett Ville: Vadsø Code postal: 9811 Pays: Norvège Adresse internet: https://www.domstol.no/Enkelt-domstol/ost-finnmark-tingrett/
VI.4.2) Organe chargé des procédures de médiation Nom officiel: Klagenemda for offentlige anskaffelser Ville: Bergen Code postal: 5805 Pays: Norvège Courriel: postmottak@kofa.no Adresse internet: http://www.kofa.no
VI.5) Date d'envoi du présent avis:
17/11/2020
 
 
C L A S S E    C P V
33600000 - Produits pharmaceutiques